XERIS BIOPHARMA HOLDINGS, INC. Consolidated Balance Sheets (in thousands, except share and par value) December 31, 2021 December 31, 2020 Assets Current assets: Cash and cash equivalents $ 67,271 $ 37,598 Short-term investments 35,162 96,190 Trade accounts receivable, net 17,456 6,875 Inventory 18,118 8,353 Prepaid expenses and other current assets 4,589 3,196 Total current assets 142,596 152,212 Property and equipment, net 6,627 6,707 Goodwill 22,859 — Intangible assets, net 131,450 — Other assets 829 232 Total assets $ 304,361 $ 159,151 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 8,924 $ 3,117 Other accrued liabilities 49,088 15,895 Accrued trade discounts and rebates 15,041 5,984 Accrued returns reserve 4,000 2,889 Other current liabilities 1,987 322 Total current liabilities 79,040 28,207 Long-term debt, net of unamortized debt issuance costs 88,067 87,021 Contingent value rights 22,531 — Supply agreement liability, less current portion 5,991 — Deferred rent 6,883 6,629 Deferred tax liabilities 4,942 — Other liabilities 1,676 3,533 Total liabilities 209,130 125,390 Commitments and contingencies (Note 16) Stockholders’ Equity: Preferred stock—par value $0.0001, 25,000,000 shares and 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2021 and 2020, respectively — — Common stock—par value $0.0001, 350,000,000 shares and 150,000,000 shares authorized as of December 31, 2021 and 2020, respectively; 124,873,316 and 59,611,202 shares issued and outstanding as of December 31, 2021 and 2020, respectively 13 6 Additional paid in capital 555,359 371,134 Accumulated deficit (460,110) (337,385) Accumulated other comprehensive (loss) income (31) 6 Total stockholders’ equity 95,231 33,761 Total liabilities and stockholders’ equity $ 304,361 $ 159,151 See accompanying notes to consolidated financial statements. 90
RkJQdWJsaXNoZXIy NTIzOTM0